BPC-157
Also known as: BPC 157, Body Protection Compound 157, Body Protective Compound 157, PL 14736
5 notable studies · 7 references
TLDR
BPC-157 is an investigational 15-amino-acid peptide studied extensively in animal models of tissue repair, gastrointestinal injury, vascular signaling, and inflammation, but human evidence remains extremely limited and its safety and effectiveness have not been established.
Research Supports
- Studied extensively in animal models of tendon, ligament, and muscle repair
- Investigated for gastrointestinal injury and protection
- Examined for effects on angiogenesis and vascular signaling
- Studied in a small number of human pilot studies for bladder/pelvic pain symptoms and short-term safety
Observations Reported in Research
- Promoted endothelial-cell migration and angiogenesis via VEGFR2-Akt-eNOS signaling in vitro (Hsieh et al., 2017)
- Produced concentration-dependent, endothelium- and nitric-oxide-dependent vasorelaxation in isolated human internal mammary artery tissue (Yildirim et al., 2026)
- Reported substantial symptom improvement in an uncontrolled 12-person pilot study of interstitial cystitis (2024)
- A 2026 review found fewer than 30 human participants across three uncontrolled pilot studies and no completed Phase II trial
- No adverse effects or meaningful lab changes observed in a 2-person IV safety pilot study (Lee and Burgess, 2025)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic 15-amino-acid peptide; gastric pentadecapeptide derivative; investigational peptide
BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence associated with a gastric protein preparation. Researchers have investigated it primarily in animal and cellular models involving gastrointestinal injury, tendon and muscle healing, blood vessels, inflammation, and tissue repair. BPC-157 has developed a substantial reputation online as a “healing peptide,” but the scientific evidence is much less mature than that description implies. Most efficacy evidence remains preclinical, human research is extremely limited, and BPC-157 is not FDA-approved for any medical use. FDA has also identified insufficient human safety information and potential concerns involving immunogenicity, peptide impurities, and characterization of compounded BPC-157 products.
What Is BPC-157?
BPC-157 is a synthetic peptide consisting of 15 amino acids. It originates from research involving a gastric protein preparation sometimes referred to as “body protection compound” or BPC. Researchers isolated and synthesized a short peptide sequence that became known as BPC-157. Much of the BPC-157 literature comes from animal experiments investigating gastrointestinal injury and tissue protection. Research subsequently expanded into tendon, ligament, muscle, bone, vascular, neurological, and other experimental injury models. Its unusually broad preclinical literature has contributed to claims that BPC-157 broadly accelerates healing. That interpretation requires caution. A compound producing effects across multiple experimental animal models does not establish equivalent effects in humans. Human evidence remains sparse. A 2026 review concluded that available clinical data involved fewer than 30 participants across three uncontrolled pilot studies and noted the absence of completed Phase II clinical trials, validated dosing regimens, and standardized pharmaceutical formulations.
What Are Researchers Studying?
Tendon, ligament, and muscle repair
BPC-157 has been investigated extensively in rodent models of tendon, ligament, and muscle injury. Researchers have reported effects involving tendon-to-bone healing, cellular migration, angiogenic signaling, and functional recovery after experimental injuries. These findings are responsible for much of BPC-157’s reputation as a tissue-repair peptide, but controlled human evidence demonstrating accelerated musculoskeletal healing remains lacking.
Gastrointestinal protection and repair
Some of the earliest BPC-157 research focused on gastrointestinal injury. Animal studies have investigated stomach lesions, intestinal injury, inflammatory gastrointestinal models, fistulas, and other forms of gastrointestinal damage. Despite this extensive animal literature, evidence demonstrating clinical effectiveness for gastrointestinal disease in humans remains insufficient. FDA's 2026 evaluation concluded there was insufficient evidence to determine effectiveness of BPC-157-related substances for ulcerative colitis.
Angiogenesis and vascular signaling
Researchers have investigated whether BPC-157 influences blood-vessel formation and vascular signaling, including pathways involving vascular endothelial growth factor (VEGF) and nitric oxide. In 2026, researchers reported that BPC-157 produced concentration-dependent relaxation in isolated human internal mammary artery tissue. The response was reduced when the endothelium was removed or nitric-oxide synthase was inhibited, supporting involvement of endothelial nitric-oxide signaling. This was an ex vivo tissue experiment, not administration of BPC-157 to patients.
Inflammation and tissue injury
BPC-157 has been investigated across numerous experimental injury models involving inflammatory signaling and tissue damage. Researchers have reported changes involving inflammatory mediators, oxidative stress, vascular responses, and tissue organization. Because these findings span different tissues and experimental models, researchers are still working to determine which mechanisms are primary and which are secondary consequences of injury repair.
Nervous-system injury and neurobiology
Animal studies have investigated BPC-157 in models involving peripheral nerve injury, spinal-cord injury, traumatic brain injury, and neurotransmitter systems. These experiments remain preclinical and do not establish BPC-157 as a treatment for neurological injury or disease in humans.
Bladder and pelvic pain conditions
A small uncontrolled human pilot study investigated BPC-157 in 12 women with interstitial cystitis. Participants received BPC-157 during a cystoscopic procedure, and investigators reported substantial symptom improvement. Because the study had only 12 participants, lacked a placebo/control group, relied heavily on patient-reported outcomes, and was conducted at a private clinic, it should be considered preliminary evidence rather than proof of effectiveness.
How Does It Work?
BPC-157 does not yet have one clearly established molecular mechanism that explains its broad experimental effects. Research has implicated several interacting pathways. One major area involves vascular signaling. Experimental studies have connected BPC-157 with VEGF-related angiogenesis and nitric-oxide signaling. The 2026 human arterial-tissue study provides direct ex vivo evidence that BPC-157 can affect vascular tone through an endothelium- and nitric-oxide-dependent mechanism. Other experimental work has investigated interactions with growth-factor signaling, inflammatory pathways, oxidative stress, cellular migration, and tissue-remodeling processes. This broad collection of proposed mechanisms is scientifically interesting but also highlights an important limitation: BPC-157 does not yet have a thoroughly characterized pharmacological mechanism in humans. A 2026 pharmaceutical-development review emphasized unresolved issues involving formulation, pharmacokinetics, permeability, pharmaceutical characterization, and the relationship between BPC-157's relatively short measured presence and longer-lasting effects reported in preclinical models.
What Does the Research Show?
Human research
Human evidence for BPC-157 remains extremely limited. A small pilot study involving 12 women with interstitial cystitis reported substantial symptom improvement after BPC-157 was administered during a cystoscopic procedure. However, the study was uncontrolled and small. A separate 2025 pilot study examined intravenous BPC-157 in only two adults. Researchers reported no adverse effects or meaningful changes in the laboratory measures examined after infusions. The authors themselves emphasized the need for further studies. Two participants are far too few to establish a human safety profile. In 2026, researchers also demonstrated BPC-157-induced vasorelaxation in isolated human internal mammary artery samples obtained during bypass surgery. This provides mechanistic human-tissue evidence but is not a clinical treatment study. A 2026 review characterized the total clinical evidence as fewer than 30 participants across three uncontrolled pilot studies, with no completed Phase II trial. Accordingly, the existence of some human research should not be confused with an established human evidence base.
Animal research
Animal research represents the overwhelming majority of the BPC-157 literature. Rodent experiments have investigated gastrointestinal injury, tendon and ligament healing, skeletal muscle injury, bone healing, blood vessels, nerve injury, spinal-cord injury, brain injury, and numerous other experimental conditions. Many studies report favorable biological or functional outcomes. However, the breadth of positive animal findings creates its own translational question: very broad activity across experimental models requires careful validation through independent replication, pharmacological characterization, and controlled human trials. Animal efficacy does not establish clinical efficacy in humans.
In-vitro research
Cellular experiments have investigated BPC-157 in fibroblasts, endothelial cells, tendon-derived cells, and other experimental systems. Reported effects include changes in cellular migration, signaling pathways associated with angiogenesis, nitric-oxide biology, and responses relevant to tissue repair. In vitro studies can help identify potential mechanisms but cannot determine whether BPC-157 safely accelerates healing in people.
Notable Studies
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
in-vitroResearchers investigated whether BPC-157 affects angiogenesis and the signaling pathways involved. Experimental findings indicated that BPC-157 promoted endothelial-cell migration and angiogenesis and implicated VEGFR2, Akt, and endothelial nitric-oxide synthase signaling. The study provided a potential mechanistic explanation for some of the vascular and tissue-repair effects reported in earlier BPC-157 experiments.
Limitations: The findings were preclinical and do not establish that BPC-157 accelerates healing in humans. Angiogenic activity may also have different consequences depending on tissue and disease context, making human safety and pharmacological characterization particularly important.
View publication →Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
humanResearchers investigated BPC-157 in 12 women with interstitial cystitis who had not responded to prior pentosan-polysulfate treatment. Participants received BPC-157 during a cystoscopic procedure around areas of bladder inflammation. Investigators reported that 10 of 12 participants described complete symptom resolution, while the remaining two reported substantial improvement.
Limitations: The study included only 12 participants and had no placebo or comparison group. Outcomes relied substantially on participant-reported improvement, and the design cannot distinguish a BPC-157 effect from procedural effects, placebo effects, natural symptom variation, or other confounding factors. The findings require confirmation in larger randomized controlled trials.
View publication →Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
humanResearchers investigated short-term laboratory and clinical responses to intravenous BPC-157 in two adults. No adverse effects were reported, and researchers did not observe meaningful changes in the measured cardiac, hepatic, renal, thyroid, or glucose-related laboratory markers during the brief observation period.
Limitations: Only two people participated, and both had previously received intravenous BPC-157. The study lacked a control group, was extremely short, and was far too small to detect uncommon adverse effects or characterize long-term safety. The absence of observed adverse effects in two participants should not be interpreted as establishing that BPC-157 is safe in humans.
View publication →Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
humanResearchers examined residual internal mammary artery tissue obtained from 12 patients undergoing coronary artery bypass surgery. BPC-157 produced concentration-dependent relaxation in artery rings with intact endothelium. The effect was substantially reduced when the endothelium was removed or nitric-oxide synthase was inhibited, supporting a role for endothelial nitric-oxide signaling.
Limitations: This was an isolated-tissue experiment rather than administration of BPC-157 to patients. Responses of arterial tissue in a laboratory bath cannot establish clinical cardiovascular effects, therapeutic benefit, dosing, pharmacokinetics, or safety in humans.
View publication →BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
animalThe authors critically reviewed BPC-157's development as a potential pharmaceutical compound, including formulation, pharmacokinetics, administration routes, preclinical findings, and available human research. They concluded that BPC-157 has a substantial preclinical literature but remains pharmaceutically underdeveloped. The review identified fewer than 30 human participants across three uncontrolled pilot studies, no completed Phase II clinical trial, no validated dosing regimen, and no standardized pharmaceutical-grade formulation.
Limitations: This was a narrative review rather than a new controlled experiment. The conclusions depend on the quality of the underlying literature, much of which consists of animal studies and very small exploratory human reports.
View publication →What We Still Don't Know
Despite decades of preclinical investigation, fundamental questions remain: - Whether BPC-157 meaningfully accelerates tendon, ligament, muscle, bone, or other tissue healing in humans - Whether gastrointestinal findings from animal models translate into clinical benefit - Human pharmacokinetics across proposed routes of administration - Short- and long-term human safety - Immunogenicity risk - Effects of peptide aggregation and impurities - Whether different BPC-157 salts or formulations behave equivalently - A validated pharmaceutical formulation - A validated human dosing regimen - Which proposed mechanisms are most important in humans - Whether very broad effects reported across animal models reproduce in rigorous independent clinical trials FDA's current assessment is especially important here: the agency states that it has no or only limited safety information for proposed administration routes and therefore lacks sufficient information to know whether BPC-157 would cause harm when administered to humans.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the BPC-157 research with you.
Get the Aminodex BPC-157 Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333.
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024.
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20–24.
- Yildirim AK, Dastan AO, Ertus MD, Ensarioglu M, Karabacak K, Pehlivanoglu B. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Journal of Clinical Medicine. 2026;15(9):3488. doi:10.3390/jcm15093488.
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. BPC-157 safety assessment.
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee materials: BPC-157 (free base) and BPC-157 acetate. 2026.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.